Kamada Ltd. (NASDAQ:KMDA) Lowered to “Sell” at Zacks Investment Research
Kamada Ltd. (NASDAQ:KMDA) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday.
According to Zacks, “Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. “
Separately, Jefferies Group LLC reissued a “buy” rating and issued a $8.00 target price on shares of Kamada in a research note on Wednesday, April 12th.
Kamada (NASDAQ:KMDA) opened at 5.75 on Tuesday. The stock’s 50 day moving average price is $7.16 and its 200-day moving average price is $6.74. The company’s market capitalization is $207.89 million. Kamada has a 12 month low of $3.76 and a 12 month high of $8.61.
Kamada (NASDAQ:KMDA) last released its earnings results on Tuesday, May 16th. The biotechnology company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by $0.08. Kamada had a negative net margin of 11.31% and a negative return on equity of 12.55%. The company had revenue of $11.65 million during the quarter, compared to the consensus estimate of $20.82 million. On average, equities research analysts predict that Kamada will post $0.06 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Kamada Ltd. (NASDAQ:KMDA) Lowered to “Sell” at Zacks Investment Research” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.dailypolitical.com/2017/07/17/kamada-ltd-nasdaqkmda-lowered-to-sell-at-zacks-investment-research.html.
Large investors have recently added to or reduced their stakes in the stock. Edmond DE Rothschild Holding S.A. raised its stake in Kamada by 17.8% in the first quarter. Edmond DE Rothschild Holding S.A. now owns 38,200 shares of the biotechnology company’s stock worth $266,000 after buying an additional 5,772 shares during the period. Norges Bank bought a new stake in Kamada during the fourth quarter worth $377,000. Acadian Asset Management LLC bought a new stake in Kamada during the first quarter worth $575,000. Finally, Renaissance Technologies LLC raised its stake in Kamada by 20.4% in the fourth quarter. Renaissance Technologies LLC now owns 227,000 shares of the biotechnology company’s stock worth $1,237,000 after buying an additional 38,500 shares during the period. 5.86% of the stock is owned by institutional investors.
Kamada Company Profile
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kamada Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.